CoSyne Therapeutics

At CoSyne, our mission is driven by incredible women scientists. 👩‍🔬💻 On this International Day of Women and Girls in Science, we’re proud to celebrate the innovators on our team.

#WomenInScience #IDWGS2026 #Biotech #BrainCancerResearch #STEM #WomenInSTEM

At CoSyne, we focus on speeding up the translation of treatments from the lab to the clinic, because we know time is the most valuable asset a patient has. We’re proud to be part of the UK’s life sciences community, working toward a day where "1 in 2" is a statistic of the past.

Today is #WorldCancerDay. In our lifetimes, 1 in 2 of us will face a cancer diagnosis. While 10-year survival rates have reached 50%, progress remains uneven for less survivable cancers like glioblastoma.

#UnitedByUnique #BrainCancer #GBM #DrugDiscovery #BrainCancerResearch

The conference provided many opportunities to seed new partnerships and establish pathways to translate our science into impact for rare disease patients in 2026. We also welcomed the chance to reconnect with the advisors, investors, and supporters who are integral to our mission.

The CoSyne team had a fantastic time at the JP Morgan Healthcare conference in San Francisco last week!

#JPM2026 #CoSyneTherapeutics #BioTech #RareDisease #GBM

The CoSyne team got together at our Christmas party last week, for an afternoon filled with delicious food, thoughtful Secret Santa gifts, and finding out who had some hidden curling talents! 🎅🎁🥌

🎄✨ Merry Christmas & happy holidays from our team to yours!

A huge thank you to the entire team and collaborators whose work made this possible! [5/5]

Our findings suggest that cytarabine could provide a targeted treatment option for a genetically defined group of patients with leptomeningeal dissemination of glioma, making an existing therapy newly actionable through biomarker guidance. [4/5]

This work highlighted a strong dependency on DNA polymerase pathways and pointed us toward cytarabine, an existing FDA-approved drug. When we tested cytarabine across several glioma models, we found that tumours with both TP53 and RB1 intact were significantly more sensitive than others. [3/5]

In this study, we used large-scale CRISPRi screening in patient-derived glioma models to identify the genetic weaknesses of these tumours. [2/5]

TP53 and RB1 are predictive genetic biomarkers for sensitivity to cytarabine in gliomas Therapeutic progress in glioma, one of the most lethal human cancers, has been limited by molecular heterogeneity and lack of biomarker-driven drug deployment. Here we used a proprietary large-scale C...

📣 Excited to share our latest pre-print in precision medicine and molecular drug response stratification in brain tumours. [1/5] www.biorxiv.org/content/10.1...

#glioblastoma #GBM #biomarkerdiscovery #patientstratification #drugrepurposing

This week, the CoSyne team are heading to the beautiful Honolulu to join the SNO meeting! 🌺🌴

Come and find us to hear about CoSyne’s latest exciting glioblastoma biomarker findings… more on that later in the week!

#SNO2025 #glioblastoma #GBM #braincancer #neurooncology #drugdiscovery #biomarkers

🧠 At CoSyne, we are proud to be supporting the International Brain Tumour Alliance (IBTA) during this year’s International Brain Tumour Awareness Week!

For more information, visit the IBTA's website here: www.theibta.org

#IBTAWeek #braintumourawareness #glioblastoma

Winner winner chili dinner! 🌶️ 🏆 It turns out that brain cells aren’t the only thing we’re good at seeding…

Congrats to the experimental bio team in Cambridge who have taken out the JCBC chilli growing contest for most chilis on a single plant!

Great to have everyone together for our company offsite yesterday! It’s always great to connect as a full team, celebrate our wins, and align on the next phase of our journey 🙌🧠🚀

#CoSyneTherapeutics #Glioblastoma #Bioinformatics #DrugDiscovery #BrainCancerResearch

We’ve got an incredible interdisciplinary team here at CoSyne Therapeutics! Mi is a senior computational biologist analysing our genomic data generated in the wet lab, and Sophie is our operations coordinator who supports the senior leadership team and wider company 🖥️🧬📋🧠

MYTH vs FACT: Think you know the truth about brain cancer? Let’s break down some common misconceptions! 🧠

Have you heard this myth before? 💭⁉️

#Glioblastoma #GBM #BrainCancer #BrainCancerResearch #BioTech

A huge congratulations to our bioinformatician Grant who conquered the great Steall Marathon in the Scottish Highlands on the weekend! He finished with an impressive time of 7:03 and placed 85 of 231 finishers. 🏃 🏔️ 🎖️

#CoSyneTherapeutics #Glioblastoma #BrainCancerResearch #Fundraising

🔔 Don't miss a thing! Our journey to fight rare neurological disease is happening on all our social media channels, and we'd love for you to join us.
➕ Follow us on all our pages to get the full story and support our mission.
#Glioblastoma #DrugDiscovery #BrainCancerResearch

If you are a UK citizen or resident, please lend your voice to this cause! [3/3]

Their mission is our mission: to accelerate progress in brain cancer treatment. They're calling on the UK government to increase research funding, standardise genomic sequencing for better-informed treatment, and enact "Right to Try" laws for those with terminal diagnoses. [2/3]

Petition: Invest in brain cancer and give rights – turn terminal into treatable Brain cancer is the biggest cancer killer of children and adults under 40, 87% with a high-grade brain tumour diagnosis die within 5 yrs, and yet it gets just 1% of the national spend on cancer.

We’re standing with Brain Cancer Justice, a new group founded by patients and advocates fighting for change. [1/3]

petition.parliament.uk/petitions/73...

#CoSyneTherapeutics #BrainCancerJustice #BrainCancer #Petition

#CoSyneTherapeutics #Glioblastoma #BrainCancerResearch #BioTech #KnowledgeGraphs

Instead of just relying on the data within the LLM compressed in its weights, the prompt contains now additional information from structured resources. Naturally, this can be also leveraged in agentic workflows that chain different tasks executed by the LLM together. [13/13]

🤖 Generative AI enhancement: Knowledge Graphs can provide structured data to large language models (LLM; for example ChatGPT) to reduce hallucinations and improve accuracy (known as retrieval augmented generation). [12/13]

📚 Biomedical literature: Which research groups are making similar discoveries? How strong is the evidence for a particular claim made in a research publication? Do we observe validation of findings/claims by other scientists? [11/13]

🔭 Beyond the drug repurposing use case:

Knowledge Graphs are transforming biomedical research (and other disciplines) in other ways too. Some examples: [10/13]

Instead of searching through scattered databases, we can ask complex questions like: "Show me all safety-approved drugs that target proteins we know are critical in GBM." The example below shows how this would work in practice. [9/13]

🔋 What makes Knowledge Graphs powerful?

Think of a Knowledge Graph as a network that connects related information, bridges different concepts, and shows the relationship between them. [8/13]

By mapping out these relationships, we can identify human-safe drugs that might be repurposed for treating GBM (and other deadly brain diseases). This could dramatically reduce the development time and risk typically required for the development of new treatments. [7/13]